Advanced Cancer Therapeutics
429 W. Muhammad Ali Boulevard
Suite 600
Louisville
Kentucky
40202
United States
Tel: 502-589-6404
Fax: 502-589-6391
14 articles about Advanced Cancer Therapeutics
-
Qualigen obtains exclusive license to novel cancer drug technology from Advanced Cancer Therapeutics
12/18/2018
Qualigen continues to strengthen its cancer drug technology portfolio
-
Advanced Cancer Therapeutics Enters Phase 1 Human Clinical Trials With First-in-Class Anti-Cancer Drug Candidate
6/4/2014
-
Advanced Cancer Therapeutics Awarded Phase I SBIR Grant to Develop Anti-cancer Drug for Novel Cancer Metabolism Target
10/11/2012
-
Advanced Cancer Therapeutics to Present Preclinical Data on Glycolysis Inhibitors at American Association for Cancer Research Annual Meeting
3/8/2011
-
Advanced Cancer Therapeutics Collaborates with Brown Cancer Center Research Scientist in Cancer Metabolism
8/10/2010
-
Advanced Cancer Therapeutics Raises $10 Million to Develop Potentially Lifesaving Cancer Treatments
7/1/2010
-
Advanced Cancer Therapeutics Receives Final $250,000 Investment From Commonwealth Seed Capital
2/23/2010
-
Advanced Cancer Therapeutics Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates
2/3/2010
-
Advanced Cancer Therapeutics Secures Exclusive License to Anti-Cancer Therapeutic from the University of Louisville's Brown Cancer Center
6/3/2009
-
James R. Ramsey, Ph.D., President University of Louisville, Joins Advanced Cancer Therapeutics Board Of Directors
9/24/2008
-
Advanced Cancer Therapeutics Appoints Gilles Tapolsky, Ph.D. to Chief Scientific Officer
8/19/2008
-
Advanced Cancer Therapeutics Licenses Technology to Develop Human Papillomavirus (HPV) Vaccine
7/23/2008
-
Advanced Cancer Therapeutics Obtains Exclusive License to Dual Mechanism Anti-Cancer Therapeutic from the University of Louisville's Brown Cancer Center
3/4/2008
-
Robert W. Rounsavall, III Joins Advanced Cancer Therapeutics Board of Directors
2/20/2008